Catatonia associated with initiating paliperidone treatment.
We present a case of catatonia, which occurred shortly after starting a new antipsychotic, paliperidone, an active metabolite of risperidone. Catatonia may be caused by a variety of conditions, including metabolic, neurologic, psychiatric and toxic processes. Interestingly, risperidone, which has been thought to cause several cases of catatonia, has also been recommended as a potential treatment. We discuss potential mechanisms for causes of drug-induced catatonia as well as potential treatment options.
McKeown
Nathanael J
NJ
Oregon Health & Science University, Department of Emergency Medicine, Oregon Poison Control Center, Portland VA.
Bryan
James H
JH
Horowitz
B Zane
BZ
J Clin Psychopharmacol. 1983 Dec;3(6):338-42
6139391
Can J Psychiatry. 2005 Mar;50(4):241-2
15898466
Int J Neuropsychopharmacol. 2001 Sep;4(3):251-7
11602030
Drugs Today (Barc). 2005 Sep;41(9):599-607
16341291
J Neuropsychiatry Clin Neurosci. 2001 Spring;13(2):303-4
11449040
Clin Neuropharmacol. 2001 Jul-Aug;24(4):228-31
11479394
Pharmacopsychiatry. 2001 Jan;34(1):25-6
11229618
Psychiatry Clin Neurosci. 1999 Feb;53(1):63-6
10201286
Am J Psychiatry. 2003 Jul;160(7):1233-41
12832234
Med Lett Drugs Ther. 2007 Mar 12;49(1256):21-3
17351558
Clin Pharmacol Ther. 1981 Aug;30(2):239-45
7249508
Arch Gen Psychiatry. 1996 Jan;53(1):82-3
8540780
J Dev Behav Pediatr. 2006 Aug;27(4):369
16906015
Acta Psychiatr Scand. 1999 Mar;99(3):223-4; discussion 224-6
10100918